Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 18
Submit an article Journal homepage
163
Views
3
CrossRef citations to date
0
Altmetric
Reviews

Reduction of blood pressure in patients with treatment-resistant hypertension

Maria Czarina Acelajado University of Alabama at Birmingham, Vascular Biology and Hypertension Program, CH19, Room 115, 1530 3rd Avenue South, Birmingham, AL 35294-2041, USA +1 205 934 9281; +1 205 934 1302; [email protected]
, MD,
David A Calhoun University of Alabama at Birmingham, Vascular Biology and Hypertension Program, CH19, Room 115, 1530 3rd Avenue South, Birmingham, AL 35294-2041, USA +1 205 934 9281; +1 205 934 1302; [email protected]; University of Alabama at Birmingham, Division of Cardiovascular Disease, Department of Medicine, Birmingham, AL, USA
&
Suzanne Oparil University of Alabama at Birmingham, Vascular Biology and Hypertension Program, CH19, Room 115, 1530 3rd Avenue South, Birmingham, AL 35294-2041, USA +1 205 934 9281; +1 205 934 1302; [email protected]; University of Alabama at Birmingham, Division of Cardiovascular Disease, Department of Medicine, Birmingham, AL, USA
, MD
Pages 2959-2971 | Published online: 19 Nov 2009

Bibliography

  • Calhoun DA, Jones D, Textor S, Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19
  • Furberg CD, Wright JT, Davis BR, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002;288:2981-77
  • Dahlof B, Devereux RB, Kjeldsen SE, Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003
  • Pepine CJ, Handberg EM, Cooper-DeHoff RM, A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
  • Leotta G, Rabbia F, Canade A, Characteristics of the patients referred to a Hypertension Unit between 1989 and 2003. J Hum Hypertens 2008;22:119-21
  • Lewington S, Clarke R, Qizilbash N, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
  • Wong ND, Franklin SS. Epidemiology of hypertension. In: Oparil S, Weber MA, editors, Hypertension. A Companion to Brenner and Rector's The Kidney. Philadelphia, PA: Elsevier Saunders; 2003. pp. 16-28
  • Pierdomenico SD, Lapenna D, Bucci A, Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant and true resistant hypertension. Am J Hypertens 2005;18:1422-8
  • Veglio F, Rabbia F, Riva P, Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin Exp Hypertens 2001;23:203-11
  • Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among patients with hypertension: the Framingham Heart Study. Am Heart J 1993;125:1148-54
  • Palatini P, Thijs L, Staessen JA, Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002;162:2313-21
  • Caro JJ, Speckman JL, Salas M, Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41-6
  • Garg JP, Elliott WJ, Folker A, Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005;18:615-26
  • Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens 2003;31:S37-42
  • De Souza WA, Yugar-Toledo JC, Bergsten-Mendes G, Effect of pharmaceutical care on blood pressure and health-related quality of life in patients with resistant hypertension. Am J Health Syst Pharm 2007;64:1955-61
  • Dolan E, Stanton A, Thijs L, Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin Outcome Study. Hypertension 2005;46:156-61
  • Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008;168:2340-6
  • Pickering TG, White WB. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008;2:119-24
  • Ben-Dov IZ, Kark JD, Ben-Ishay D, Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension 2007;49:1213-14
  • Amici A, Cicconetti P, Sagrafoli C, Exaggerated morning blood pressure surge and cardiovascular events. A 5-year longitudinal study in normotensive and well-controlled hypertensive elderly. Arch Gerontol Geriatr 2009;49:e105-9
  • Muxfeldt ES, Cardoso CR, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med 2009;169:874-80
  • Muxfeldt ES, Bloch KV, Nogueira NR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit 2003;8:181-5
  • Rodrigues CS, Bloch KV, Noguiera AR. Office blood pressure and 24-h ambulatory blood pressure measurements: high proportion of disagreement in resistant hypertension. J Clin Epidemiol 2009;62:745-51
  • Pickering TG, Miller NH, Ogedegbe O, Call to action on use and reimbursement for home blood pressure monitoring. A joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 2008;52:10-29
  • Douma S, Petidis K, Doumas M, Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008;371:1921-6
  • Calhoun DA, Nishizaka MK, Zaman MA, Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-6
  • Umpierrez GE, Cantey P, Smiley D, Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007;30:1699-703
  • Strauch B, Zelinka T, Hampf M, Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003;17:349-52
  • Gallay BJ, Ahmad S, Xu L, Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001;37:699-705
  • Eide IK, Torjesen PA, Drolsum A, Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004;22:2217-26
  • Logan AG, Perlikowski SM, Mente A, High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001;19:2271-7
  • Goncalves SC, Martinez D, Gus M, Obstructive sleep apnea and resistant hypertension. A case control study. Chest 2007;132:1858-62
  • Coresh J, Wei GL, McQuillan G, Prevalence of high blood pressure and elevated serum creatinine level in the United States. Arch Intern Med 2001;161:1207-16
  • Fox CS, Muntner P. Trends in diabetes, high cholesterol, and hypertension in chronic kidney disease among U.S. adults: 1988–1994 to 1999–2004. Diabetes Care 2008;31:1337-42
  • Funder JW, Carrey RM, Fardella C, Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:3266-81
  • Nishizaka MK, Pratt-Ubunama M, Zaman MA, Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005;18:805-12
  • Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000;90:394-400
  • Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Characterization of resistant hypertension. Arch Intern Med 2008;168:1159-64
  • Ramachandran SK, Josephs LA. A meta-analysis of clinical screening tests for obstructive sleep apnea. Anesthesiology 2009;110:928-39
  • Kushida CA, Littner MR, Morgenthaler T, Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005;28:499-521
  • Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004;125:112-27
  • Nieman LK, Biller BMK, Findling JW, The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526-40
  • Turnbull F, For the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003;362:1527-35
  • Neal B, Macmahon S, Chapman N, . Blood Pressure Lowering Collaboration. Treatment Trialists' Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000;356:1955-64
  • Chobanian AV, Bakris GL, Black HR, Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
  • Pimenta E, Gaddam KK, Oparil S, Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009;54:475-81
  • Jackson KC, Sheng X, Nelson RE, Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther 2008;30:1558-63
  • Shaya FT, Du D, Gbarayor CM, Predictors of compliance with antihypertensive therapy in a high-risk Medicaid population. J Natl Med Assoc 2009;101:34-9
  • Brixner DI, Jackson KC II, Sheng X, Assessment of adherence, persistence and costs among valsartan and hydrochlorothiazide retrospective cohorts in free and fixed-dose combinations. Curr Med Res Opin 2008;24:2597-607
  • Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan and hydrochlorothiazide. A randomized controlled trial. Hypertension 2009;54:19-22
  • Taler SJ, Textor SC, Augustine JE. Resistant hypertension. Comparing hemodynamic management to specialist care. Hypertension 2002;39:982-8
  • Ray WA, Griffin MR, Downey W, Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1989;I:687-90
  • Wanich R, Davis J, Ross P, Effects of thiazides on rates of bone mineral loss: a longitudinal study. Br Med J 1990;310:1303-5
  • Ernst ME, Carter BL, Goerdt CJ, Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-8
  • Multiple Risk Factor Intervention Trial Research Group. Mortality after 10½ years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990;82:1616-28
  • Lombes M, Farman N, Bonvalet JP, Identification and role of aldosterone receptors in the cardiovascular system. Ann Endocrinol 2000;61:41-6
  • Staessen J, Lijnen P, Fagard R, Rise in plasma aldosterone concentration during long-term angiotensin II suppression. J Endocrinol 1981;91:957-65
  • Jorde UP, Ennezat PV, Lisker J, Maximally recommended doses on angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844-6
  • Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-30
  • Lane DA, Shah S, Beevers DG. Low dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007;85:291-4
  • Dahlof B, Sever PS, Poulter NR, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding benzoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
  • Chapman N, Dobson J, Wilson S, Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45
  • Saha C, Eckert GJ, Ambrosius WT. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005;46:481-7
  • Chapman N, Chang CL, Dahlof B, Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008;118:42-8
  • Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press 2009;18:74-7
  • Hermida RC, Smolensky MH. Chronotherapy of hypertension. Curr Opin Nephrol Hypertens 2004;13:501-5
  • Hermida RC, Ayala DE, Calvo C, Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005;46:1053-9
  • Epstein BJ. Efficacy and safety of darusentan: a novel endothelin receptor antagonist. Ann Pharmacother 2008;42:1060-9
  • Weber MA, Black H, Bakris G, A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomized, double-blind, placebo-controlled trial. Lancet 2009: published online 14 September 2009, doi:10.1016/S0140-6736(09)61500-2
  • Filippone JD, Bisognano JD. Baroreflex stimulation in the treatment of hypertension. Curr Opin Nephrol Hypertens 2007;16:403-8
  • Illig KA, Levy M, Sanchez L, An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter Phase II Rheos feasibility trial. J Vasc Surg 2006;44:1213-18
  • Krum H, Schlaich M, Whitbourn R, Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81
  • Townsend RR, DiPette DJ, Goodman R, Combined alpha/beta blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther 1990;48:665-75

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.